Gilead Sciences Inc (GILD)
90.19
+0.43
(+0.48%)
USD |
NASDAQ |
Nov 22, 16:00
90.16
-0.03
(-0.03%)
After-Hours: 20:00
Gilead Sciences Free Cash Flow: 9.431B for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
September 30, 2024 | 9.431B |
June 30, 2024 | 6.896B |
March 31, 2024 | 7.90B |
December 31, 2023 | 7.421B |
September 30, 2023 | 7.853B |
June 30, 2023 | 8.926B |
March 31, 2023 | 8.386B |
December 31, 2022 | 8.344B |
September 30, 2022 | 9.007B |
June 30, 2022 | 9.415B |
March 31, 2022 | 9.953B |
December 31, 2021 | 10.80B |
September 30, 2021 | 9.491B |
June 30, 2021 | 8.472B |
March 31, 2021 | 8.698B |
December 31, 2020 | 7.518B |
September 30, 2020 | 8.16B |
June 30, 2020 | 8.51B |
March 31, 2020 | 8.244B |
December 31, 2019 | 8.319B |
September 30, 2019 | 8.039B |
June 30, 2019 | 7.639B |
March 31, 2019 | 6.758B |
December 31, 2018 | 7.476B |
September 30, 2018 | 7.912B |
Date | Value |
---|---|
June 30, 2018 | 8.432B |
March 31, 2018 | 10.56B |
December 31, 2017 | 11.31B |
September 30, 2017 | 12.14B |
June 30, 2017 | 13.78B |
March 31, 2017 | 15.15B |
December 31, 2016 | 16.30B |
September 30, 2016 | 18.56B |
June 30, 2016 | 18.17B |
March 31, 2016 | 18.88B |
December 31, 2015 | 20.50B |
September 30, 2015 | 17.73B |
June 30, 2015 | 17.83B |
March 31, 2015 | 16.43B |
December 31, 2014 | 12.26B |
September 30, 2014 | 10.07B |
June 30, 2014 | 6.872B |
March 31, 2014 | 3.686B |
December 31, 2013 | 2.915B |
September 30, 2013 | 2.693B |
June 30, 2013 | 2.656B |
March 31, 2013 | 3.001B |
December 31, 2012 | 2.798B |
September 30, 2012 | 3.314B |
June 30, 2012 | 3.468B |
Free Cash Flow Range, Past 5 Years
6.896B
Minimum
Jun 2024
10.80B
Maximum
Dec 2021
8.587B
Average
8.429B
Median
Free Cash Flow Benchmarks
Eli Lilly and Co | -2.275B |
Merck & Co Inc | 14.84B |
Pfizer Inc | 8.227B |
Amgen Inc | 6.283B |
Vertex Pharmaceuticals Inc | -1.352B |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | 4.309B |
Cash from Investing (Quarterly) | -710.00M |
Cash from Financing (Quarterly) | -1.379B |
Free Cash Flow Per Share (Quarterly) | 3.324 |
Free Cash Flow to Equity (Quarterly) | 4.269B |
Free Cash Flow to Firm (Quarterly) | 4.412B |
Free Cash Flow Yield | 8.35% |